Back to Search
Start Over
Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study
- Source :
- Frontiers in Molecular Biosciences, Frontiers in Molecular Biosciences, Vol 7 (2021)
- Publication Year :
- 2021
- Publisher :
- Frontiers Media SA, 2021.
-
Abstract
- Purpose: The study aims to retrospectively investigate the efficacy and safety of sorafenib combined with transarterial chemoembolization (TACE) (TACE+Sor) vs. TACE combined with sorafenib plus immune checkpoint inhibitors (TACE+Sor+ICIs) in treating intermediate and advanced TACE-refractory hepatocellular carcinoma (HCC).Materials and Methods: This study was approved by the ethics committee of Lisui Hospital, Zhejiang University, China. From January 2016 to June 2020, 51 eligible patients with intermediate or advanced TACE-refractory HCC received TACE+Sor (n = 29) or TACE+Sor+ICIs (n = 22). The differences in tumor response, adverse events (AEs), progression-free survival (PFS), and overall survival (OS) were compared between the two groups. Factors affecting PFS and OS were determined by Cox regression.Results: The disease control rate was higher in the TACE+Sor+ICIs group than in the TACE+Sor group (81.82 vs. 55.17%, P = 0.046). Compared with the TACE+Sor group, PFS and OS were prolonged in the TACE+Sor+ICIs group (median PFS: 16.26 vs. 7.30 months, P < 0.001; median OS: 23.3 vs. 13.8 months, P = 0.012). Multivariate analysis showed that BCLC stage, alpha-fetoprotein and treatment were independent factors of PFS; BCLC, Child-Pugh class, ablation after disease progression and treatment were independent predictive factors of OS. Four patients in the TACE+Sor+ICIs group and three patients in the TACE+Sor group suffered from dose reduction or interruption (18.18 vs. 10.34%, P = 0.421). The incidence of ICI-related AEs in the TACE+Sor+ICIs group was well-controlled.Conclusion: The therapeutic schedule of TACE+Sor+ICIs demonstrated efficacy and safety in intermediate and advanced TACE-refractory HCC.
- Subjects :
- Oncology
Sorafenib
medicine.medical_specialty
overall survival
transarterial chemoembolization
Biochemistry, Genetics and Molecular Biology (miscellaneous)
Biochemistry
immune checkpoint inhibitors
03 medical and health sciences
0302 clinical medicine
Refractory
Internal medicine
Medicine
Molecular Biosciences
Progression-free survival
Adverse effect
lcsh:QH301-705.5
Molecular Biology
Original Research
business.industry
Proportional hazards model
Retrospective cohort study
hepatocellular carcinoma
medicine.disease
adverse events
BCLC Stage
lcsh:Biology (General)
030220 oncology & carcinogenesis
Hepatocellular carcinoma
TACE-refractory
sorafenib
030211 gastroenterology & hepatology
business
progression-free survival
medicine.drug
Subjects
Details
- ISSN :
- 2296889X
- Volume :
- 7
- Database :
- OpenAIRE
- Journal :
- Frontiers in Molecular Biosciences
- Accession number :
- edsair.doi.dedup.....1ae1c7801d4ade514bcef8eec81de24d
- Full Text :
- https://doi.org/10.3389/fmolb.2020.609322